The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells

被引:117
|
作者
Delgado, M
Gonzalez-Rey, E
Ganea, D
机构
[1] Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA
[2] Inst Consejo Super Invest Cient, Inst Parasitol & Biomed, Granada, Spain
来源
JOURNAL OF IMMUNOLOGY | 2005年 / 175卷 / 11期
关键词
D O I
10.4049/jimmunol.175.11.7311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tolerogenic dendritic cells (DCs) play an important role in maintaining peripheral tolerance through the induction/activation of regulatory T cells (Treg). Endogenous factors contribute to the functional development of tolerogenic DCs. In this report, we present evidence that two known immunosuppressive neuropeptides, the vasoactive intestinal peptide (VIP) And the pituitary adenylate cyclase-activating polypeptide (PACAP), contribute to the development of bone marrow-derived tolerogenic DCs in vitro and in vivo. The VIP/PACAP-generated DCs are CD11c(low)CD45RB(high), do not up-regulate CD80, CD86, and CD40 following LPS stimulation, and secrete high amounts of IL-10. The induction of tolerogenic DCs is mediated through the VPAC1 receptor and protein kinase A, and correlates with the inhibition of I kappa B phosphorylation and of NF-kappa Bp65 nuclear translocation. The VIP/PACAP-generated DCs induce functional Treg in vitro and in vivo. The VIP/DC-induced Treg resemble the previously described Tr1 in terms of phenotype and cytokine profile, suppress primarily Th1 responses including delayed-type hypersensitivity, and transfer suppression to naive hosts. The effect of VIP/.PACAP on the DC-Treg axis represents an additional mechanism for their general anti-inflammatory role, particularly in anatomical sites which exhibit immune deviation or privilege.
引用
收藏
页码:7311 / 7324
页数:14
相关论文
共 50 条
  • [41] VASOACTIVE INTESTINAL PEPTIDE AND ASTHMA
    BARNES, PJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (16): : 1128 - 1129
  • [42] VASOACTIVE INTESTINAL PEPTIDE IN CIRRHOSIS
    ELIAS, E
    MITCHELL, SJ
    BLOOM, SR
    LANCET, 1975, 2 (7948): : 1312 - 1312
  • [43] VASOACTIVE-INTESTINAL-PEPTIDE
    SAID, SI
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1986, 9 (02) : 191 - 200
  • [44] RADIOIMMUNOASSAY OF VASOACTIVE INTESTINAL PEPTIDE
    EBEID, AM
    MURRAY, P
    HIRSCH, H
    WESDORP, RIC
    FISCHER, JE
    JOURNAL OF SURGICAL RESEARCH, 1976, 20 (04) : 355 - 360
  • [45] VASOACTIVE INTESTINAL PEPTIDE IN THE LUNG
    SAID, SI
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1988, 527 : 450 - 464
  • [46] RECEPTORS FOR VASOACTIVE INTESTINAL PEPTIDE AND SECRETIN ON SMALL INTESTINAL EPITHELIAL-CELLS
    BINDER, HJ
    LEMP, GF
    GARDNER, JD
    AMERICAN JOURNAL OF PHYSIOLOGY, 1980, 238 (03): : G190 - G196
  • [47] Antigen specific immunotherapy generates CD27+ CD35+ tolerogenic dendritic cells
    Wu, Zhiqiang
    CELLULAR IMMUNOLOGY, 2013, 283 (1-2) : 75 - 80
  • [49] PREFERENTIAL BINDING OF VASOACTIVE INTESTINAL PEPTIDE TO HEPATIC NONPARENCHYMAL CELLS
    GARDNER, DF
    KILBERG, MS
    WOLFE, MM
    MCGUIGAN, JE
    MISBIN, RI
    AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 248 (06): : G663 - G669
  • [50] A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells
    Sharma, A
    Walters, J
    Gozes, Y
    Fridkin, M
    Brenneman, D
    Gozes, I
    Moody, TW
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2001, 17 (03) : 331 - 339